The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (…
We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…
Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…
The asthma therapy market consists of many well-established treatments, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s…
Since 2018, the U.S. treatment landscape for migraine prophylaxis has undergone a major expansion with the entry of the novel calcitonin gene-related peptide (CGRP)-targeting monoclonal antibodies…
The launch of several novel therapies and multiple label expansions for premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL…
Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the rarity of the disease, the potential commercial opportunities for drugs…
Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. However,…
The treatment landscape for advanced HR-positive / HER2-negative breast cancer is continually evolving. CDK4/6 inhibitors, such as Pfizer’s Ibrance and Novartis’s Kisqali, are commonly used…
Acute and chronic heart failure (HF) have distinct treatment pathways, and both are covered in this report. Although much progress has been made in the pharmacological management of HF, this…
Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular beats of the atrial chambers of the heart. AF is the most common arrhythmia treated in clinical practice…
The gastroesophageal cancer therapy market (including gastric, gastroesophageal junction, and esophageal cancer) is rapidly evolving and experiencing substantial growth, largely driven by the…
The demand for safe and effective obesity drugs is increasing due to the rising prevalence of obesity and the growing interest in incretin therapies, whose efficacy is approaching that of bariatric…
Migraine is a major public health concern in China, where it affects approximately 65 million people, making it the world’s largest migraine population. The disease is a heterogeneous condition…
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. Characterized by the thickening and stiffening of tissues in the lungs, it…